Low-molecular-weight heparin therapy in Percutaneous Coronary Intervention: The NICE 1 and NICE 4 trials

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. E, 2000, Pages

  Young, John J ^a   Kereiakes, Dean J ^a   Grines, Cindy L ^b  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Enoxaparin; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG COMBINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SAFETY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; ENOXAPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK FACTORS; SAFETY;

EID: 0034567257     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ryan TJ, Bauman WB, Kennedy JW, et al. ACC/AHA task force report: Guidelines for percutaneous transluminal coronary angioplasty. A report of the ACC/AHA task force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1993;22:2033-2054.
2. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996;276:811-815.
3. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Agency for health care policy and research and the National Heart, Lung, and Blood Institute, Public Health Service. Rockville, MD, 1994: pp. 6-12.
4. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated clotting time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
5. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
6. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
7. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction - Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999;100:1593-1601.
8. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". J Invas Cardiol 2000;12(Suppl A):1A-5A.
9. Kereiakes DJ, Grines C, Fry E, et al. Combination enoxaparin and abciximab during percutaneous coronary intervention: A new standard of care? Curr Intervent Reports 2000;2:157-164.
10. Kereiakes DJ, Grines C, Fry E, et al. Abciximab-enoxaparin interaction during percutaneous coronary intervention: Results of the NICE 1 and 4 trials. J Am Coll Cardiol 2000;35:92A.
11. Kereiakes DJ, Fry E, Barr L, et al. Enoxaparin-abciximab combination for percutaneous coronary intervention: final results of the NICE 4 trial. Am J Cardiol 2000;86:141.
12. The EPISTENT investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
13. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.